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ABSTRACT 
Serum autoantibodies play a key role in systemic autoimmune rheumatic diseases for diagnostic, 
classification and prognostic purposes. Research of new autoantibodies has been very active in the 
last decade in rare connective tissue diseases such as systemic sclerosis and poly/dermatomyositis, 
with new biomarkers entering the clinical practice. Immunoprecipitation of protein and/or RNA 
components of the target autoantigens constitutes the gold standard method for the discovery of new 
autoantibodies in a screening setting but is considered time- and labor-intensive and, accordingly, is 
performed only in a few laboratories worldwide. As a result, alternative techniques such as ELISA 
and immunoblotting are often preferred for large-scale testing, despite the lack of standardization.   
The aims of the present project are (1) to set up protein- and RNA- immunoprecipitation in our 
laboratory and (2) to describe serum autoantibodies identified in our series of patients affected by 
systemic autoimmune rheumatic diseases. During the PhD program we were able to perform 
correctly protein-and RNA-immunoprecipitation in our laboratory as demonstrated by positive 
reference sera, and then by the identification of known but also new and rare autoantibodies, as 
represented by two new patterns immunoprecipitated in systemic sclerosis, corresponding to serum 
anti-hnRNP-L and anti-mitochondrial antibodies. In psoriatic arthritis we also analyzed the 
concentration of circulating levels of LL37, a recently established target of autoimmune response at 
the skin level, and we identified an increased production in a subset of patients. In conclusion, 
performing protein- and RNA-immunoprecipitation as a screening method in our laboratory allows 
a more complete and specific autoantibody analysis that cannot be performed by the commercial 
techniques available nowadays, and further analysis of the role of LL37 in psoriatic arthritis patients 
may help in the identification of a new biomarker in this condition.  
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INTRODUCTION 
1. AUTOANTIBODIES IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES. 
Systemic Autoimmune Rheumatic Diseases (SARDs) include chronic conditions characterized 
by the presence of specific serum autoantibodies (autoAbs) and a panel of symptoms related to 
the autoimmune injury of joints, skin and internal organs. The clinical expression of SARDs can 
be very heterogeneous, and they can be divided into three main groups, as shown in Figure 1 
panel A. Among SARDs, Connective Tissue Diseases (CTDs) refer to chronic inflammatory and 
autoimmune conditions that affect the connective tissue, and are characterized by a non-organ 
specific autoimmune reaction characterized by serum autoAbs [1, 2]. This group includes 
Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome (SjS), Systemic Sclerosis (SSc), 
Poly/Dermatomyositis (PM/DM), and some forms that do not fulfill the established diagnostic 
criteria called undifferentiated connective tissue disease (UCTD) [3, 4], while the presence of 
multiple CTDs (SLE, SSc and PM) in the same patient with positive anti-U1RNP antibodies is 
defined mixed connective tissue disease (MCTD) [5]. As for arthritis, we can divide them in two 
main groups: the first one is represented by Rheumatoid Arthritis (RA), a chronic inflammatory 
polyarthritis affecting synovial joints (and more rarely internal organs) that is characterized by 
positivity of Rheumatoid Factor (RF) and anti-cyclic citrullinated peptide (CCP) in up to 70% of 
patients, and for this reason an RA patient can be called seropositive; the second group is 
represented by seronegative arthritis such as psoriatic arthritis (PsA), ankylosing spondylitis and 
reactive arthritis that are negative for RF and anti-CCP antibodies as required in the diagnostic 
criteria [6]. The third group of SARDs is represented by vasculitidies, conditions characterized 
by the inflammation of small, medium or large vessels, in which the only biomarker available for 
their diagnosis is represented by ANCA (anti-neutrophil cytoplasmic antibodies), positive in a 
reduced number of cases represented by eosinophilic granulomatosis with polyangiitis, 
granulomatosis with polyangiitis and microscopic polyangiitis [7].  
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The diagnosis of CTDs relies not only on clinical symptoms and signs, but also on the 
identification of autoAbs that are associated with specific clinical manifestations and for this 
reason they are also called disease-marker antibodies and they are so important that they are part 
of the diagnostic criteria for some of these CTDs (Figure 1, panel B) [1, 2, 8]. The importance 
of autoAbs relies also on the fact that they can be present years before the clinical manifestations 
of SARDs, and they can be used also for their predictable value as they can characterize early 
and undifferentiated autoimmune diseases [8]. For example, the positivity of anti-nuclear 
antibodies (ANA) in the presence of a symptom such as Raynaud’s phenomenon is part of the 
criteria for very early diagnosis of SSc, and this early diagnosis can change the follow-up, 
prognosis and therapeutic approach in SSc patients [9].  
As shown in Figure 1 panel B, many known autoAbs are used as routine clinical tests for 
diagnostic and classification purpose, but many new autoAbs are not part of standard laboratory 
tests and more still need to be identified. In fact, in recent years there has not been any 
identification of new autoAbs in SLE and SSc with significant impact on clinical medicine, 
while several new autoAbs have been identified in PM/DM patients but they can be searched 
only in research and not in routine settings [10].   
1.1- Autoantigens targeted by autoantibodies.  
Antigens recognized by autoAbs are self-antigens first characterized in 1948 with the LE cell 
phenomenon described as the engulfment of denatured nuclear material of a cell by a neutrophil or 
macrophage [11]. In 1976 anti-Sm antibodies were identified in patients affected by SLE [11], and 
in the following years thousands of cellular proteins have been identified but only a few decades of 
autoantigens (autoAgs) have been described in SARDs. AutoAgs are usually macromolecular 
particles defined as multiprotein or nucleoprotein complexes with important functions in the cells 
such as RNA splicing and chromatin organization [12]. DNA-protein autoantigens include the 
histones/chromosomes, NOR90, centromeres, Ku antigen, while RNA-protein complex autoAg are 
UsnRNPs (U1RNP, Sm antigens), U3/fibrillarin and Th/To. These complexes tend to be localized 
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in different subcellular compartments and this is the reason why they appear in specific patterns at 
immunofluorescence, as for the nucleolar staining in SSc autoantibodies [10, 11].  
The autoimmune response directed against autoAgs takes place through multiple ways and it is 
triggered by an abnormal processing of self-antigens by antigen-presenting cells (APCs). The 
presence of altered protein-protein or protein-nucleic acid interactions and the somatic mutation of 
self-antigens (such as p53) may trigger the immune system through activation of autoreactive T 
cells and production of autoAbs that may spread within the molecule or other components [10, 11]. 
The presence of altered patterns of protein degradation such as abnormal protease expression or 
apoptosis pathways can enhance the presentation of cryptic peptides to autoreactive T cells [10].  
These autoimmune mechanisms are very selective because only a limited numbers of proteins are 
seen by IP using radiolabeled cell extract that contains thousands of proteins. In addition, in SSc 
and PM/DM presence of more than one disease-marker autoAb is uncommon: they are mutually 
exclusive and they do not change overtime despite a variation in the clinical features of the 
autoimmune disease. 
In conclusion, we can say that the exact mechanism leading to autoAb production and manifestation 
of disease in the form of SARDs is unknown, but several hypothesis suggest that a possible trigger 
of the autoimmune response could be a quantitative or qualitative change in protein, DNA or RNA 
structure, and formation of cryptic epitopes expressed by APCs that are responsible for no or 
incomplete tolerance and can trigger an autoimmune response [13, 14].  
1.2- Anti-nuclear (ANA) and ENA (extractable nuclear antigens) antibodies.  
Serum ANA are autoAbs directed against self-antigens that are produced in systemic autoimmune 
conditions, or also in the presence of organ-specific autoimmune diseases (i.e. autoimmune 
thyroiditis), cancer or infections [1, 12, 15]. The standard method used test for the identification of 
ANA is indirect immunofluorescence (IIF) [16], which is routinely performed in the laboratories 
worldwide and allows the identification of the ANA pattern and titer. The nuclear staining patterns 
are usually classified into speckled, homogeneous, nucleolar and centromere and reported routinely 
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[16], but there are other less frequent patterns that can be seen only in a limited number of patients. 
As for the titer, ANA positivity ≥1:160 is considered clinically significant by most routine 
autoimmunity laboratories and strong positivity is associated with the presence of autoimmune 
disorders, while titers ≤1:160 are present in up to 20% of healthy people, mainly in the elderly and 
in female population [17] as we also recently demonstrated in a study on ANA prevalence and risk 
of SARDs in a specific area of Northern Italy [18]. The ANA positivity is poorly specific, and in the 
suspect of SARDs it is necessary to require further testing for anti-ENA (extractable nuclear 
antigen) specificities. With this term we refer to a group of autoAgs originally identified as antibody 
targets in people with SARDs that are commonly composed of non-histone ribonucleoproteins, 
called by the name of the donor who provided the prototype serum (i.e. Sm for Smith), or the name 
of the disease in which the antibodies were found (i.e. SS-A and SS-B for SjS antigen A and B; Scl-
70 for the first identification in a SSc patient) [19]. In the suspect of SARDs, routine laboratory 
testing requires both ANA with titer and anti-ENA; for example, when we suspect SLE in a patient 
we could receive a report of homogeneous ANA pattern at high titer which is consistent with 
positivity to anti-dsDNA antibodies, and ENA may be positive for anti-Sm/RNP antibodies that are 
very specific for SLE and are also included in the 1982 ACR SLE classification criteria [20].  
As mentioned, autoAbs are central to the diagnosis of SARDs and are included in the diagnostic 
and classification criteria of several diseases (Figure 1, panel B). In particular, ANA, anti-dsDNA 
and anti-Sm/RNP are part of the SLE diagnostic criteria established in 1982 [20]; anti-Ro/SSA and 
anti-La/SSB antibodies are included in the SjS classification criteria defined by Vitali et al [21]; for 
the diagnosis of SSc, the identification of three autoAbs (anti-centromere, anti-topo I/Scl70, anti-
RNA polymerase III) is included in the last revision of SSc diagnostic criteria published in 2015 
[22]; the presence of anti-Jo-1 antibodies identifies patients with the so-called anti-synthetase 
syndrome [23]. 
1.3- Immunoprecipitation.  
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In the last decade, several new methods have been developed to increase the number of tests to be 
performed in routine autoimmunity laboratories and to use quantitative automated high-volume 
solid phase methods instead of standard manual methods. These new assays have been first tested in 
dedicated specialized laboratories but now they are used in high-throughput routine laboratories and 
this has raised the problem of quality control mainly for reproducibility, sensitivity, specificity and 
clinical interpretation [24-26]. These problems have become so important that in 2010 a task force 
organized by the American College of Rheumatology (ACR) has developed a set of 
recommendations for ANA testing [16], stating that IIF remains the gold-standard for ANA testing 
and that in-house assays for autoAbs testing should be standardized according to national or 
international standards (i.e. CDC).  
As for immunoprecipitation (IP), this is the method preferred for the identification of autoAbs in 
SARDs [2, 27] as it allows the first identification of many autoAbs that are then used in routine 
clinical practice though the development of commercial assays, as for anti-RNApol III antibodies in 
SSc patients. These were identified and tested by IP for decades until the development of a specific 
anti-RNApol III ELISA that is currently used in routine autoimmunity laboratories [19]. IP has the 
advantage of showing not only known but also unknown autoAbs in a single assay, and to allow the 
further identification of the bands of the target autoAgs using mass spectrometric analysis of 
purified proteins. These positive aspects of IP are associated to some disadvantages for the use of 
IP, mainly represented by the fact that it requires dedicated personnel, it is not automated, it 
requires experience in the set up and interpretation of results, and it needs dedicated equipment and 
radioactivity for protein-IP. For these limitations, IP is used only in a few research laboratories 
worldwide, and the need for quick and high-throughput methods led us to patent an alternative 
method for the identification of two autoAbs detected in SSc patients, called anti-Th/To and -
U3/fibrillarin, through the combination of IP samples preparation followed by RT-qPCR [28]. This 
method avoids the need to run urea-PAGE gels that are very delicate and that lead to qualitative and 
not quantitative results in the detection of RNA bands. However, the use of methods alternative to 
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IP for autoAb analysis (such as ELISA and immunoblotting) still needs validation and it is still 
matter of debate in the international rheumatology community.  
1.4- Autoantibodies identified in SARDs by IP.  
The importance of autoAbs has been progressively highlighted by their inclusion in several sets of 
classification and diagnostic criteria, starting from the first sets of criteria in the 1970s-1980s for 
SLE and PM [20, 29] and followed by the most recent criteria for SSc in which autoAbs were 
considered as important as specific clinical features and capillaroscopy alterations in the 
classification of patients [22]. Table 1 shows the main serum autoAbs that can be identified by 
protein-and RNA-IP in SSc, PM and DM patients, with a description of the target antigen and its 
features recognized by protein-IP and/or RNA-IP. For SSc, the identification of ACA is still based 
on IIF, even if it is possible to detect specific centromere proteins (CENP A-F) by other techniques 
such as line blot, immunoblot and ELISA [27]. No ACA specific band can be detected by IP, even 
if we show the presence of a new pattern associated to ACA in our Results section. Other SSc 
autoAbs can be identified by IP based on their target antigen: topo I is present as a strong 110kD 
band with a smear toward high molecular weight, presumable due to phosphorylation [30]; RNA 
polymerase antibodies are identified through a set of several bands as described in Table 1 [31]; 
Th/To are clearly visible by RNA-IP through the reactivity of the two RNA bands called 7-2 and 8-
2 RNAs [32, 33]; similarly, U3/ fibrillarin antibodies can be identified by the U3RNA band at 
RNA-IP as first described in 1985 [34] and –PM/Scl that characterize the overlap between PM and 
SSc features are detected by protein-IP [35, 36]. As for PM patients, we can identify several anti-
synthetase antibodies by protein- and RNA-IP [37] (Table 1), and in the last decade several new 
autoAbs have been detected in PM patients thanks to these techniques: this is the case of the less 
common anti-synthetase antibodies such as anti-PL-12, PL-7, EJ, and OJ  that seem to be associated 
with peculiar clinical manifestations within the classical anti-synthetase syndrome [38-43]; and also 
the anti-SRP antibodies usually associated to a form of necrotizing and not inflammatory myopathy 
[44]. Another field of active research of autoAbs is represented by DM, in which the only known 
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autoAb has been anti-Mi-2 for decades [45], but in the last decade several other autoAbs such as 
anti-MJ/NXP-2 [46], -MDA5 [47], -TIF1β [48], -TIF1γ/α [49] were identified and their clinical 
correlations have been increasingly studied in different ethnic groups [37].  
Beside the mentioned autoAbs listed in Table 1, several other autoAbs can be identified but they 
are not considered specific for particular SARDs. This is the case of anti-Ro/SSA (Ro60) and -
La/SSB that can be identified in several conditions, first of all SjS but also SLE, SSc and PM/DM, 
or anti-Ro52 and Ago2/Su antibodies that have been identified in several conditions without a clear 
clinical significance [50].   
2. REPRESENTATIVE DISEASES INCLUDED IN THE PRESENT WORK. 
2.1- Systemic Sclerosis (SSc).  
SSc is an autoimmune disease of unknown origin characterized by microvascular damage and 
progressive fibrosis of skin that in severe cases can affect internal organs such as heart, lungs, and 
kidneys. As most autoimmune diseases, it is more common in female patients (female:male 4:1) 
with age of onset at 30-60 years. In Italy, it is considered a rare disease due to its low prevalence, 
which is estimated to be 1/6.500 adults in the general population, with differences linked to 
ethnicity and geographic areas [51]. One of the typical symptoms at SSc onset is the Raynaud’s 
phenomenon, expression of severe peripheral vaso-constriction, but the clinical aspects of SSc can 
be very heterogeneous and they can develop sometimes very quickly and aggressively, and 
sometimes more slowly and over a period of decades [52]. The etiology and the pathogenesis of 
SSc are unknown, but two processes, fibrosis and microvascular occlusion, characterize the 
pathological findings seen in all involved organs in SSc patients [53]. Several mechanisms are 
proposed in the pathogenesis of SSc disease, such as (i) activation of the adaptive and innate 
immune system and activation of endothelial cells; (ii) release of cytokines (i.e. TGF-β, PDGF, IL-
4) from platelets, macrophages, and T-cells; (iii) cytokine activation of fibroblasts to increase 
extracellular matrix production; (iv) altered expression of VEGF [54, 55]. Concerning this aspect, 
we studied levels of serum VEGF concentration in our SSc patients, and we could see that this 
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molecule is variably expressed in SSc patients with pulmonary interstitial involvement [56] and 
unpublished data] and it could be considered as a biomarker of this specific clinical feature in SSc. 
The two main forms in which SSc can develop in patients are called diffuse or limited according to 
the extent of skin fibrosis as established by LeRoy in 1988 [57]. Each of these forms is associated 
with the presence of a specific autoAb profile, and the great importance of autoAbs in SSc is 
demonstrated by their inclusion in the recent diagnostic criteria developed by ACR/EULAR in 2013 
[22]. In fact, the occurrence of ANA is present in virtually all SSc patients [58] and they are very 
characteristic [27, 59, 60] in SSc patients for the following reasons:  
1- they are specific for SSc, as they are not detected in other autoimmune diseases or immune-
mediated mechanisms;  
2- they are positive since the onset of SSc and they don’t change during the disease course;  
3- they are unique and mutually exclusive [61], because the detection of multiple positivity in the 
same SSc patient is very rare;  
4- they characterize clinical subsets of SSc (diffuse vs limited), and also particular clinical 
manifestations in SSc, for example anti-RNAPIII antibodies are usually identified in diffuse SSc 
with high risk of scleroderma renal crisis [62, 63].  
The most frequently identified autoAbs in SSc are ACA (30%), anti-topo I (30%), and -RNA pol III 
(4-20%), and in fact these three specificities are the only ones included in the 2013 ACR/EULAR 
criteria for SSc diagnosis [22]. However, several other autoAbs can be identified in SSc patients 
and they can have an important role for their clinical and prognostic value, as for anti-U3/fibrillarin 
and anti-Th/To antibodies [1]. One of the main limitations in the study of autoAbs in SARDs such 
as SSc is the lack of routine methods of testing [27, 64] that could be used worldwide. In fact, 
protein- and RNA-IP still represent the gold standard for the analysis of antigenic components 
recognized by sera of SSc patients, and for this reason we applied these techniques to our SSc 
patients without known autoantibody specificity (ACA and anti-topo I negative) despite ANA 
positive pattern and high titer.  
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2.2- Poly/Dermatomyositis (PM/DM). 
PM/DM are two conditions within the spectrum of Idiopathic Inflammatory Myopathy and they are 
CTDs characterized by muscle inflammation (myositis) and in the case of DM also skin 
inflammation with unknown etiology and pathogenesis. Several hypotheses have been proposed and 
discussed as triggers of PM/DM, and among these we have genetic predisposition, infections (i.e. 
CMV, EBV) and cancer in PM/DM paraneoplastic forms [65], but no certain factor has been 
identified so far [66] and Ceribelli et al, Clin Rev Allergy Immunol 2015, in press]. Both PM and 
DM are rare diseases because of their low prevalence and incidence in the general population 
(annual incidence of 5-10 cases/million people; prevalence 6-7 cases/100.000 people), and they 
affect female more than male (ratio 2.5:1) with bimodal distribution: some cases are defined 
juvenile because the onset is typically at 5-15 years of age, while other cases are diagnosed in adult 
people aged 30-50 years [67, 68]. Myositis is the main symptom of PM/DM, represented by muscle 
inflammation that can be diagnosed based on histological analysis of muscle biopsy, which can 
differentiate PM and DM based on the location of the inflammatory infiltrate, usually perivascular 
in DM while it surrounds muscle fibers in PM [65]. Myositis is described by patients as 
symmetrical proximal muscular weakness, and it can affect muscle fibers at different sites causing 
severe symptoms such as dysphagia and respiratory-muscle weakness. If not treated, muscle 
inflammation leads to fibrosis and muscle atrophy which are responsible for severe and irreversible 
disability [65, 69]. Inflammation in PM/DM can be systemic and it may be associated with other 
symptoms such as lung inflammation (interstitial lung disease), skin disease, arthritis and 
Raynaud’s phenomenon, and all these aspects worsen the PM/DM patients’ prognosis and 
therapeutic benefits of immunosuppressive medications [69]. The first diagnostic criteria for 
PM/DM were published in 1975 by Bohan and Peter [29, 70] to define PM and DM mainly based 
on clinical, instrumental and histopathological criteria. AutoAbs were not present in this first set of 
criteria, and they were included only later, in the diagnostic criteria proposed by Targoff in 1997 
[23]. In fact it had become increasingly clear that autoAbs are very important in PM/DM patients 
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because they are positive in about 50-80% of cases and they have clinical associations that help the 
clinician in patients’ diagnosis and classification [71]. This is particularly true for anti-Jo-1 
(histidyl-tRNA synthetase) antibodies that were included in this set of new classification criteria 
defined by Targoff et al, and they are present in 15-20% of patients affected by PM with a specific 
syndrome called anti-synthetase syndrome characterized by a set of symptoms such as myositis, 
interstitial lung disease, polyarthritis, mechanic’s hands, fever and Raynaud’s phenomenon [72]. 
This is a clear example of how antibodies can define specific clinical features thus having a 
predictive and prognostic value [72]. However, many PM/DM patients (up to 50%) still do not have 
known autoAbs despite the presence of high-titer ANA by IIF. Clinical research is going on to 
identify target autoAg in PM/DM patients, and the increased number of cases collected worldwide 
is of great importance also to characterize the clinical phenotype associated to specific autoAbs. For 
this reason, since 2015 we became part of the Euromyositis Network (https://euromyositis.eu) 
which represents an International collaboration research and treatment database for myositis 
specialists.  
2.3- Psoriatic Arthritis (PsA). 
Arthritidies can be defined as seropositive when the characteristic RF and  anti-CCP antibodies are 
present, or they are called seronegative when these antibodies are negative and the diagnosis can be 
made only at the moment of clinical onset of arthritis [73-75]. Rheumatoid Arthritis (RA) is the 
prototype of seropositive arthritis, while in the group of seronegative arthritis we include psoriatic 
arthritis (PsA, associated to skin or nail psoriasis), reactive arthritis (secondary to genitourinary or 
bowel infections), spondyloarthritis (affecting joints and spine), and enteropathic arthritis 
(associated to inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis) as shown 
in Figure 1 panel A [6, 76]. Differently from RA, PsA is characterized by inflammation not only of 
joints but also of peri-articular structures, leading to manifestations such as arthritis, enthesitis and 
dactilytis. No present parameter can be used for the diagnosis of PsA, and the only method of 
evaluating risk of spondylitis is the positivity to HLA-B27 gene and/or the increase of inflammation 
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markers such as ESR or CRP [77, 78]. Skin psoriasis (PsO) is a common condition affecting 2-4% 
of the general population, but only 25-40% of PsO patients can develop PsA and skin disease may 
develop after the onset of the joint inflammation, so this factor does not always help in the diagnosis 
of PsA, and a strong effort has been done recently in the search for a new biomarker of PsA [79]. 
Among the new biomarkers, the interleukin IL23/Th17 pathway has been promising mainly for 
pathogenic and therapeutic approaches [80], while the analysis of PsA patients through several 
approaches such as multiplex panels, proteomics, epigenetics and genetic alterations different from 
HLA-B27, have been proposed to help in the identification of a new PsA biomarker for early 
diagnosis and follow-up, but also for the response prediction to biologic therapies [81-84]. The 
etiology of PsA is unknown, but recent reports have supported presence of serum autoAbs with 
cross-reactivity for autoAg shared by skin and joints [85]. These reports show a possible 
autoimmune origin of PsA, and a role of skin antigens in the activation of innate and adaptive 
immunity in PsA that may be represented by a molecule called LL37 that has been described as the 
autoAg inducing the T-cell response in the skin of PsO patients. LL37 is a cleavage product of one 
of the major human anti-microbial peptides, cathelicidin [86], and it seems to have DNA- and 
RNA-sensing capacity and immunomodulatory properties (i.e. chemotactic function; pro-
angiogenic action) important in skin immune defense and disease. LL37 basal production in the 
skin is physiologically low, while it is overexpressed in PsO plaques and in the serum of patients 
with PsO [87] and it is the only form of cathelicidin found in PsO skin [88]. In PsO plaques, 
extracellular DNA and RNA released from dying cells together with increased LL37 levels 
constitute a pro-inflammatory stimulus initiating and amplifying cutaneous inflammation via 
dendritic cell activation [89]. However, LL37 also plays an anti-inflammatory role by targeting 
another key player in PsO pathogenesis, IL-1beta, via the AIM2 inflammasome [90]. In patients 
with RA and in a murine model of arthritis an increased expression of LL37 in the synovium and 
serum anti-LL37 autoantibodies have been observed [91], thus suggesting a role of B cell-mediated 
LL37 response in arthritis pathogenesis. LL37 has been identified in the skin microbiota also in 
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newborn infants, and it is possible that due to environmental factors (i.e. keratinocyte apoptosis 
after UV exposure) and/or genetic predisposition it could trigger an autoimmune response against 
self-antigens that are responsible for PsO and in predisposing people also to PsA [92]. Moreover, 
LL37 may be able to alter the immune system of the host through the interaction with APCs and 
then activation of B and T cells against self-antigens for mechanisms of molecular mimicry. In fact, 
LL37 is not only present in the skin but circulating LL37 T-cells have been identified in PsO 
patients [93] and they may be responsible for the activation of the innate and immune response also 
leading to PsA. 
Based on these recent reports we decided to study our PsA patients in two different directions: 1) 
screening of our PsA patients by protein- and RNA-IP in order to evaluate the possible presence of 
autoAbs to be used as serum biomarkers for the diagnosis, clinical association and therapeutic 
choices in PsA patients; 2) analysis of LL37 concentration in the serum and in the synovial fluid of 
PsA patients, to evaluate the presence of this component as marker of disease or inflammation 
activity. 
2.4- Behçet Disease (BD).  
Over the last 25 years we witnessed strenuous efforts to set classification and diagnostic criteria 
adequate for vasculitidies, but no clear result has been achieved [94-96]. With a few exceptions 
represented by Takayasu arteritis [97], polyarteritis nodosa [98] and Behçet Disease (BD) [99], all 
other vasculitidies have no recognized classification criteria. In 1994, a set of classification criteria 
was defined by the Chapel Hill group in which the size of the affected vessels was used to 
discriminate among the different vasculitis [100], and these criteria were further revised in 2012 
[101] also to add the difference between primary and secondary forms, for examples those 
associated to hepatitis B or C. No biomarker has been identified to help in the distinction of these 
several vasculitis, so the diagnosis still is performed on a clinical, instrumental or histological 
setting leading to different therapeutic approaches [102]. The only autoAb identified so far in a few 
vasculitis is represented by serum ANCA (anti-neutrophil cytoplasm antibodies) discovered in the 
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mid-eighties, but no further progress has been made in this field of research for vasculitis. ANCA 
can be classified as P (perinuclear) or C (cytoplasmic) according to the pattern visible by indirect 
immunofluorescence staining, but this requires confirmation by solid phase assays (i.e. ELISA) for 
the antigen recognized, that is proteinase 3 (PR3) by c-ANCA and myeloperoxidase (MPO) by p-
ANCA [103-105]. BD belongs to the family of vasculitis because it is a chronic vascular 
inflammatory disease characterized by symptoms affecting internal organs and usually 
characterized by three main symptoms: oral and genital aphtous lesions and ocular manifestations 
such as uveitis [106]. BD can be characterized less frequently by additional symptoms such as 
arthritis, renal and gastrointestinal disease, and skin lesions revealed by the pathergy test [106]. BD 
is a rare disease as the estimated prevalence in Europe of 1,5-15,9 cases every 100.000 inhabitants 
in Europe, with highest number of BD patients in Turkey (20-420 cases every 100.000 inhabitants) 
[107, 108], and it mainly affects male patients contrary to what observed in most autoimmune 
diseases. The etiology and the pathogenic mechanisms are not known, and controversy is still 
present for what concerns its inflammatory or autoimmune nature [109]. Previous reports have 
shown the presence of autoantibodies in BD patients, such as ANCA [110], ASCA (antibodies 
against saccharomyces cerevisiae) [111], and antibodies against phosphatidylserine and ribosomal 
phosphoproteins [112], but no specific signature autoAb has been identified so far, and for these 
reasons we performed protein- and RNA-IP also on a set of patients affected by BD.  
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UNMET NEEDS. 
Unmet need# 1. There are no serum biomarkers for a reproducible, non invasive, early diagnosis of 
systemic autoimmune rheumatic diseases and previous reports clearly showed that a 2-year 
treatment delay is associated with irreversible joint and organ damage. In particular rare conditions 
such as SSc, PM/DM, seronegative arthritis, and vasculitis are characterized by a plethora of 
poorly-prevalent serum autoAbs, often with clinical implications in the small minority of positive 
patients. We foresee that a more complete panel of autoAbs in larger cohorts of patients would 
allow a better definition and ultimately impact the management of these cases. 
Unmet need# 2. Uncommon presentations and clinical phenotypes are challenging possibilities in 
the management of rare SARDs. The identification of new serological markers such as autoAbs in 
SARDs could increase the chance for early diagnosis and treatment also for patients who have less 
common and specific disease features.  
 
GENERAL AIMS 
Aim# 1. To set up protein and RNA-IP in our laboratory for routine testing of samples from 
patients affected by SARDs. 
Aim# 2. To identify known, rare and new autoantibodies in patients affected by SSc, PM/DM, PsA 
and BD, through the analysis of immunoprecipitated bands. 
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PATIENTS AND METHODS 
Patients 
Sera from 188 consecutive patients affected by SARDs were collected in our Rheumatology 
outpatient clinic in 2013-2015 and stored in our laboratory of Autoimmunity and Metabolism in 
Humanitas Research Hospital (Rozzano, Milan, Italy). Each serum sample was tested once by 
protein-IP and once by RNA-IP, and positive samples were retested for confirmation. Inclusion 
criteria for sera collection were: (i) diagnosis of SSc with positive ANA (with a nucleolar, speckled, 
or homogeneous pattern, different from centromere -ACA), and negative ENA for serum anti-topo I 
and –RNA pol III; (ii) diagnosis of undifferentiated connective tissue disease (UCTD)/pre-SSc, a 
condition in which the systemic autoimmune disease does not fulfill the accepted classification 
criteria for a specific CTD [113] and in the case of pre-SSc patients have only few disease features 
(i.e. Raynaud’s phenomenon, nailfold capillaroscopy changes) with ANA positive antibodies but no 
other clinical feature suggestive of SSc [114] ; (iii) diagnosis of PM/DM with unknown ENA 
despite ANA positivity at routine clinical testing; (iv) diagnosis of PsA following the CASPAR 
criteria [6]. Through these inclusion criteria we were able to collect 63 SSc sera, 22 sera from 
patients affected by Idiopathic Inflammatory Myopathies such as PM/DM and anti-synthetase 
syndrome, and 58 sera from patients affected by PsA, to perform protein- and RNA-IP (Figure 2). 
An additional set of sera from 45 patients affected by BD was collected by our collaborator Dr. 
Luca Cantarini (U.O.C. Reumatologia, Dipartimento di Scienze Mediche, Chirurgiche e 
Neuroscienze; Azienda Ospedaliera Universitaria Senese; Ospedale Santa Maria alle Scotte; Siena, 
Italy) and tested by protein and RNA-IP (Figure 2).  
For the analysis of concentration of LL37 in PsA patients we tested serum and synovial fluid 
samples obtained in the same visit with venipuncture and knee arthocentesis, respectively, for three 
consecutive patients with active PsA evaluated in our outpatient clinic in 2014.  
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The study has been conducted in accordance with the Declaration of Helsinki and its subsequent 
modifications. All patients provided written informed consent and the protocol was reviewed and 
approved by the local ethical committee. 
 
Methods 
SERUM AND SYNOVIAL FLUID.  
Patients’ serum (and plasma) is obtained from whole blood through centrifugation at 2000g for 15 
minutes, and then stored in -20°C freezer until use. Synovial fluid is centrifuged at 980g for 10 
minutes and divided in aliquots stored in -80°C freezer until use.  
REFERENCE SERA FOR IP (POSITIVE CONTROLS).  
As reference sera to validate protein- and RNA-IP, we used ANA reference standards obtained from 
the Centers for Disease Control and Prevention (CDC, Atlanta, USA) that are available for clinical 
or commercial laboratories as quality controls, through the Autoantibody Standardization 
Committee (www.autoab.org) and the collaboration with the administrator of this website, Dr. 
E.K.L. Chan at the University of Florida (Gainesville, USA). We received 19 reference human sera 
for our experiments: homogeneous/RIM pattern, La/SSB, speckled pattern (U1-RNP,SSB, SSA),  
U1 RNP, Sm nuclear antigen, nucleolar pattern (U3RNP/fibrillarin), Ro/SSA, centromere pattern 
(ACA), topoI/Scl70, Jo-1, PM/Scl (PM-1), rRNP/Ribosomal P, MPO-ANCA, PR3-ANCA, anti-
CCP, anti-cardiolipin (epitope beta2 GPI)EY2C9, and anti-cardiolipin (epitope beta2 GPI) HCAL. 
They were lyophilized and resuspended with 500µl of deionized water as recommended, just before 
use, and then stored at -20°C.  
PROTEIN-IMMUNOPRECIPITATION (IP).  
The following protocol has been modified from [115]:  
Cell culture: radiolabeled cell extract is prepared using K562 cells (human erythroleukemia cell 
line). Cells are thawed 2-3 days before use and grown in RPMI-1640 with 10% FBS, 100x L-
glutamine, 100x Pen-Strep, 100x HEPES in a 5% CO2 atmosphere, at 37˚C.  
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Radiolabeling: K562 cells are collected by centrifuge (300 X g for 5minutes in a tabletop 
centrifuge), in a concentration of 10
8
 cells cultured in 45ml of complete methionine-cysteine free 
35
S-labeling culture medium in a 250ml flask. A quantity of 4.2mCi of 
35
S-methionine/cysteine is 
added and cells are incubated for 12-14hours at 37 ˚C in a 5% CO2 atmosphere. Cells incorporate 
35
S-methionine/cysteine for protein synthesis during growth and proliferation. After 12-14hours 
radiolabeling, PBS is added to the culture and cells are divided into 15ml tubes, centrifuged (300 X 
g, 5min), supernatant is aspirated, and cell pellet is used fresh or frozen at -80˚C until use. 
Protein A Sepharose (PAS) beads: PAS are prepared as solution 50% (v/v) with dH2O, then a 1/100 
amount of 2M tris-HCl pH7.5 is added to a final concentration of 20mM and 10% NaN3 to a final 
concentration of 0.1%. PAS beads can be stored at 4 ˚C in this buffer, until used.  
Preparation of PAS beads with purified antibodies: serum (or plasma) stored frozen or at 4˚C can be 
used, usually 8 µl added to 40 µl of 50% (v/v) PAS beads, to allow IgG to bind to PAS 
immediately; 500µl of 0.5M NaCl NET/MP-40 buffer are then added and the rack is wrapped using 
plastic film and rotates for 1hour - overnight at 4˚C.  
Preparation of radiolabeled cell extract: when the PAS beads with purified antibodies are ready for 
IP, cell extract is prepared. For a standard reaction, radiolabeled cell extract from ~2 x 10
6
 
cells/sample is used; 2 ml of 0.5M NaCl NET/NP-40 are added to the frozen cell pellet (~2 x 10
7
 
cells, final cell concentration 10
7
/ml), then 1:100 PMSF (Phenylmethylsulfonyl fluoride; 50mM in 
absolute ethanol) and aprotinin (from bovine lung aseptically filled solution in 0.9% NaCl and 0.9% 
benzyl alcohol) are added.  Because a sonicator was not available for use with radioactive 
35
S-K562 
cells, we tested two alternative methods for antigen extraction: (i) vortexing for 60 seconds for three 
times, leaving the pellet on ice between the cycles to avoid heating; (ii) 5 cycles of freezing in dry 
ice and thawing in 37°C waterbath for 1 minute at each step (Figure 3). As shown in Figure 3, 
results were comparable among these methods, and we decided to use vortexing cycles in our 
protocol instead of sonication. After vortexing, cell lysate is transferred to microcentrifuge tubes 
and centrifuged at 9000 X g for 30 minutes at 4˚C. The supernatant is carefully collected to avoid 
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disturbing the small pellet and ~160 µl of cell extract/sample is a standard quantity used in this 
condition to run samples twice in acrylamide gels for screening purpose.  
Incubation with cell lysate: the antibody-coated PAS beads are collected by microcentrifuging for 8 
seconds, the supernatant is aspirated and two washes with 1ml of 0.5M NaCl NET/NP-40 are 
performed. To each tube with PAS beads, 160 µl of cell extract is added per sample. Tubes are 
placed on a plastic rack, wrapped with plastic film and rotate end over end for 1hour at 4 ˚C.  
Washing beads: beads are washed 4 times as follows: microcentrifuge for 8 seconds, aspirate 
supernatant, add 1ml of 0.5M NaCl NET/NP-40, wash inside of the cap by inverting once, 
microcentrifuge for 8 sec. Then one wash is performed with the same steps but with 0.15M NaCl 
NET/NP-40 buffer. After the washes, 50µl of sample buffer (1.5ml 2M TRIS pH 6.8, 0.6ml 1% 
bromphenol blue, 3ml 2-mercaptoethanol, 4.8ml 25%SDS, 6ml glycerol, 4.1ml dH20) are added and 
samples are frozen at -80 ˚C or -20 ˚C until use. Samples are boiled before running gels, for 3 
minutes, and samples are then centrifuged for 8 seconds. After this step, they are ready to be used 
and usually 20-25µl of sample are used in each lane for the SDS-PAGE gel. 
SDS-PAGE gels: 8% or 12.5% SDS-PAGE gels are run (running buffer: 1x Tris glycine, 90mM 
Tris, 90mM boric acid, 2mM Na2EDTA) to fractionate according to the molecular weight: the 
smallest proteins that can be fractionated on 8% gels are ~25kD, while proteins of >100kD are not 
separated well on 12.5% gels. When running large or medium size gels, it takes 3-5hours at a 
constant voltage of 100-130V for the tracking dye front to reach to the bottom of the gels. When 
gels are ready, the stacking gel is cut off (leave 1-2 mm of stacking gels) and gels are stained for 
30-60 minutes with Coomassie blue solution (30% methanol, 10% gracial acetic acid, 0,1% 
Coomassie brilliant blur R250, 60% dH20). After this step, gels are destained in the destaining 
solution (35% methanol, 10% gracial acetic acid, 55%dH20) overnight.  
Fluorography: after staining and destaining, fluorography is performed as follows:  
1. DMSO (dimethyl sulfoxide) is added twice to eliminate water residues from the gel; for each 
cycle, gels are left in DMSO for 30 min on a shaker;  
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2. PPO (2.5-diphenyloxazole) is added after discarding DMSO to enhance weak signals from 
35
S; it 
is prepared as 20% (weight/volume) PPO in DMSO and the gel with PPO is left on the shaker for 
1hour.  
3. After these steps with DMSO and PPO, gels are washed several times to remove DMSO and 
make PPO precipitate in the gels. At this point, clear gels turn into white and opaque upon washing 
with water. Removing DMSO is also critical to make thinner non-sticky gels after drying. The 
washing step is repeated for at least 30 minutes. At this point, blue signals corresponding to 
immunoglobulin light and heavy chains, and the molecular weight marker are clearly visible.    
4. When gels are ready for drying, glycerol is added to a concentration of ~3%.The gel is placed on 
a piece of filter paper and set on the gel dryer at 60 ˚C for 3 hours.  
Autoradiography: after the drying step, in the darkroom the gel is placed in a film cassette in direct 
contact with X-ray (GE Healthcare) film. The half-life of 
35
S is 89 days, and usually, the signal can 
be detected after 3 days of exposure, but if the radioactivity is weak, it is necessary to expose gels 
longer. The cassette containing exposed films is left for 3-5 days at -70 ˚C before developing. 
Detection of the radioactive signal was performed with developing reagents (fixer and developer, 
Kodak) for a variable time (1-15 minutes), depending on the intensity of the radioactive signal.  
Protein-IP interpretation: Each film is labeled by sera code, positions of molecular weight marker, 
date of development, number of exposure days, and percentage of the SDS-PAGE gel. As a basic 
rule in interpretation of IP, observation of any protein bands that are present in a particular lane but 
not in other lanes means that they are specifically recognized by antibodies in the serum. 
Interpretation of specificity of autoAbs by IP is primarily based on the mobility of 
immunoprecipitated proteins by the sample, ideally by comparing with the size and the pattern of 
proteins immunoprecipitated by reference sera. Reference sera (positive controls) and negative 
controls (normal human serum) are run in every gel.  
RNA-IMMUNOPRECIPITATION (IP).  
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The following protocol has been modified from [115]: small RNA components of autoAg 
recognized by sera from SARDs patients can be identified based on IP analysis of RNAs similar to 
the above described immunoprecipitation procedure for proteins using radiolabeled K562 cells. The 
main differences in the protein- and –RNA-IP protocols are shown in Table 2. Due to concerns for 
strong radiation produced by 
32
P-orthophosphate labeled cells that was used for RNA-IP, silver 
staining analysis of RNAs is now the non-radioactive procedure most used worldwide, and it is the 
technique that we set up in our lab. Steps for preparing PAS beads stock and incubation with sera 
are the same as the method for protein-IP. Beads after incubation with sera can be stored in at 4°C 
for several days in NET/NP-40 buffer that must be aspirated before adding cell extract. 
Cell lysate: Unlabeled K562 cells (either frozen pellet or fresh cells) are used at 5 x10
6
 cells/sample 
because this concentration of cells is considered enough to detect RNA components for all autoAb 
that recognize RNA-protein complex. For the RNA-IP protocol we were able to use the sonicator 
for 45 seconds (twice) at duty cycle 30%, output control 3 (Branson, Sonifier) because K562 cells 
are not radiolabeled. K562 cell lysate is then transferred to microfuge tubes, centrifuged for 30 min 
at 9000 Xg at 4°C. PAS beads incubated with sera are washed while clearing the cell lysate. The 
supernatant is carefully collected avoiding cell pellet and cell extract is added on beads, usually 200 
microliter/sample but this volume can be adjusted depending on experiments. Samples are put on a 
plastic rack, wrapped with a plastic film and rotated at 4°C for 1hour.  
Preparation of total RNA sample as a standard: 20 microliter (extract from ~5x10
5
 cells) of cell 
lysate are put in an Eppendorf tube, and 400 microliter of 0.15M NET/NP-40IGEPAL, 16 
microliter of 25% SDS, 40 microliter of 3M Na acetate pH 5.2 are added. For RNA extraction, 400 
microliter of phenol/chloroform/isoamyl alcohol (25: 24: 1, pH 5.2 for RNA extraction; Fisher) are 
added. Each Eppendorf tube is then vortexed vigorously for 1 minute, and spinned for 1 minute at 
room temperature at 9000 Xg. Supernatant is transferred to a clean new tube avoiding the protein 
layer to avoid contamination, in a volume of 300 microliters, and 900 microliter of 100% (200 
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proof) ethanol are added, then mixed well by inverting tubes. Total RNA sample is ready after 
leaving the tubes at -80°C overnight and centrifuge at 12000 rpm for 15 minutes. 
Washing beads: this step is performed as described for protein-IP (see protocol above).  
Extraction of RNAs from the immunoprecipitates: as for total RNA preparation as standard, 400 
microliter of  0.15M NaCl  NET/NP-40, 16 microliter of 25% SDS, and 40 microliter of 3M Na 
acetate pH 5.2 are added to each sample after incubation with K562 cell lysate and the washing 
steps. For RNA extraction, 400 microliter of phenol/chloroform/isoamyl alcohol (25: 24: 1) are 
added and each sample is first vortexed vigorously for 1 minute, then spinned for 1 minute (9,000 
Xg at room temperature). A volume of 300 microliters is harvested from the top layer, avoiding the 
protein layer, and 900 microliter of 100% (200 proof) ethanol are added, then samples are mixed 
gently by inverting tubes. Tubes are left at -80°C overnight. 
Preparation of RNA samples for urea-PAGE: the following day, RNA samples are microcentrifuged 
at 9,000 Xg for 15 minutes in a cold room, supernatant can be discarded and aspirated using a thin 
Pasteur pipette. Tubes are left under biological safety hood to dry.  
Preparation of urea-PAGE gel: RNA samples are run in a 12% urea-PAGE gel, prepared as follows: 
21 g of urea, 20 ml of 30% acrylamide/bis, 5 ml of 10 X TBE, 300 microliters of ammonium 
persulfate (10% APS in milliQ water), and 30 microliter of TEMED in final volume of 50ml 
adjusted with milliQ H2O.  
Urea-PAGE: when the gel is ready, a pre-run at 400 volt constant voltage is started trying to keep 
the gel temperature between 55 - 60°C (running buffer 1xTBE). A volume of 50 microliter of urea-
PAGE sample buffer is added to each sample tube and vortexed to dissolve RNA. After the pre-run, 
samples are loaded in the UREA-PAGE gel (20 microliter/lane) after washing quickly each well 
using Hamilton microsyringe. In fact, high concentration of urea keeps coming out from the gel into 
the wells and may disturb samples to stay in the bottom of wells. The run is started at 400V and it 
continues for 1.5-2hours until the xylene cyanol dye (second dye in purple color) reaches the 
bottom of the gel (it may go out).  
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Silver staining of nucleic acids (Bio-Rad Silver Stain Plus): follow the manufacturer’s instruction. 
After detecting signals gels were dried for 2 hours at 60°C on a gel dryer and conserved. 
RNA-IP interpretation: RNAs detected in RNA-IP samples become visible bands in the urea-PAGE 
gel and their migration allows the correct interpretation when compared to total RNA as standard 
and to positive reference sera. For example, the positivity of anti-Th/To antibodies is recognized by 
the immunoprecipitation of 8-2 and 7-2RNAs, while anti-synthetase antibodies recognize 
autoantigens that have tRNA as a component (i.e. tRNA
his
 for anti-Jo-1).     
IP-WESTERN BLOT for anti-hnRNP antibodies in SSc patients.  
1- Crosslinking of IgG to PAS beads: the following protocol was used and modified from  [116]: 50 
µl of patients’s sera and 500 μl of 0.5M NaCl NET/NP40 are added to 60µl of 50% (v/v) PAS 
beads and incubated overnight. The following day, PAS beads are washed twice with 1ml 0.5M 
NaCl NET/NP40. Each sample is then washed 3 times with 1ml of 0.2M triethanolamine (TEA) pH 
8.4, then 1ml of 20mM DMP (dimethyl pimelimidate) in 0.2M TEA Ph 8.4 are added and samples 
rotate at room temperature for 2 hours. Samples are then washed with 0.2M TEA and blocked with 
1ml of 50mM TRIS HCl pH 7.6, they rotate at room temperature for 1 hour and samples are then 
washed with washing buffer (0.5M NaCl NET/NP40) for IP.  
2- IP-Western Blot: This is the protocol we followed, modified from [117]: cell extract from 
unlabeled K562 cells (~70million cells; sonication is performed with two 45-seconds cycles after 
adding 4ml 0.5M Nacl NET/NP40, 40µl PMSF and 40µl Aprotinin). While spinning the cell extract 
at 12.000RPM for 30 minutes in cold room, samples are washed once with 1ml 0.5M NaCl 
NET/NP40. The K562 cell supernatant is collected and divided in the samples (ex. 200µl/sample) 
that rotate for 1 hour in the cold room. After preparing 8% SDS-PAGE gel (stacking+resolving 
small gel, as in the protein-IP protocol), and after adding the running buffer (1 liter for 2 gels= 
800ml dH20+200ml 5X tris-glycine+ 4ml 25%SDS), samples are added (15 µl/well of samples and 
7µl of molecular weight marker) and run at 100V for 10 minutes, then increased to 130V (total run 
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time of 1 hour). At the end of the run the gel is positioned in the transfer buffer (48mM TRIS, 
39mM glycine, 20% methanol, pH 9.2) and the transfer is started for 90 minutes at 300A constant.  
After the transfer, the membrane is placed in Ponceau Red for a few minutes, then it is removed and 
the membrane is washed for a few times with dH20 and blocking buffer (5% milk in PBST) is added 
overnight.  
As primary Ab we used mouse monoclonal anti- hnRNPC1+C2 (Abcam; 1:1000 diluted in blocking 
buffer+PBS) and anti-hnRNP-L (Abcam; 1:2000 in blocking buffer+PBS), incubated for 3 hours. 
After primary Ab incubation, we washed the membrane 3 times with TBST, and then incubated 
each membrane with HRP goat anti-mouse IgG (Fisher Scientific; 1: 3000 diluted in blocking 
buffer+PBS) for 45 minutes. After incubation with the secondary Ab, we washed the membrane 3 
times with TBST and then added the chemiluminescent reagent (Millipore) for 5 minutes. The 
signal was detected after exposing the membranes to the X-ray film (GE Healthcare) for 10 
seconds, and the film is then developed by fixer and developer liquids (Kodak).  
ANTI-LL37 ELISA.  
LL37 concentration in patients’ sera (40µl) and synovial fluids (40µl) was measured by ELISA 
(Bioassay Technology Laboratory) according to manufacturer’s instructions. Optical density was 
measured by VERSAmax microplate reader and analyzed using SoftMax Pro program (Molecular 
Devices, Inc), then converted into units using a standard curve created by standards included in the 
ELISA. 
 
STATISTICAL ANALYSIS. 
The Student’s t test, Mann-Whitney or Fisher’s exact test were used for comparisons between 
groups. In the analysis of LL37 concentration, values were analyzed as units and the cut-off was 
established as mean ± 3 standard deviations (SD). Statistical significance was defined as p≤0.05. 
Statistical analyses were performed using Prism 6.0 for Windows (GraphPad Software Inc., La 
Jolla, CA).  
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RESULTS 
1- REFERENCE SERA. 
To verify the correct performance of protein-IP, we tested reference sera known to 
immunoprecipitate specific antigens with RNA and protein components that are recognized based 
on their molecular weight, as shown in Figure 4. In particular, we tested anti-Ro/SSA, -La/SSB, -
topo I positive samples and one normal human control (panel A). We were able to see the IP 
patterns of these autoAbs based on the evidence of Ro 60kD antigen, La 48kD antigen (associated 
to weak Ro60 positivity as commonly seen), and topoI 110kD antigen, while no specific band was 
detected by the normal human serum (NHS). Similarly, we tested for RNA-IP some of the CDC 
reference sera that are known to immunoprecipitate RNA bands, as shown in Figure 4, panel B. 
We were able to detect anti-Sm antibodies through the identification of U2-U1-U4-U5-U6 RNA 
bands, we identified the-U1 RNA band in the anti-U1RNP positive reference serum, and we 
observed the Y-RNAs that characterize anti-Ro/SSA antibodies in their nucleic acid component. 
These specificities were all run together with total RNA samples as standard. Negative samples 
have no band in RNA-IP (Figure 4, panel B).  
These results demonstrate the adequate set up of protein- and RNA-IP to identify reference autoAbs 
through the identification of their known antigenic patterns and molecular weight.  
 
2- SYSTEMIC SCLEROSIS (SSc).  
We tested by protein-IP and RNA-IP the SSc sera collected in the years 2013-2015 in our outpatient 
clinic. These patients (n=63) were consecutively enrolled from a total of 130 SSc patients followed 
regularly in our outpatient clinic, and we initially excluded SSc patients already characterized by 
routine clinical testing as ACA (61 cases) and -topo I (21 cases) positive, because these autoAbs are 
considered to be mutually exclusive.  
Through protein-IP and RNA-IP we were able to identify additional autoAbs in SSc patients, 
defined as rare autoAbs that are not routinely tested by autoimmunity laboratories worldwide 
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(Tables 1 and 3). These SSc sera were considered negative for ENA autoAbs until that moment 
despite ANA positive pattern also at high titer and clear manifestations of SSc disease. Thanks to 
the use of protein- and RNA-IP in our lab we were able to reduce the number of SSc sera with 
unknown antibody from 14 to 4 (Figure 5, panel A), thus giving important diagnostic and 
prognostic information to the clinician for better management of SSc patients. Moreover, thanks to 
the identification of uncommon autoAbs we can use these sera as internal standards for future 
reference as positive controls, instead of using CDC reference sera. In particular we were able to 
detect the following uncommon SSc autoAbs: anti-Th/To (n=2), -SRP (n=1), -Ago2/Su (n=1, 
associated with –topo I), and -U3RNP/fibrillarin (n=3) (Figure 5, panel C). One SSc serum showed 
positivity for anti-replication protein A (RPA) antibodies (Figure 5, panel B). This autoAb is a rare 
specificity recognized by the heterotrimer of subunits of 70/32/14kD, identified so far in patients 
affected by SLE and SjS, but not in SSc patients. The rarity of this autoAb is well reflected by the 
identification of 9 cases out of 1119 sera screened by protein-IP in a previous report, and only 5 of 
these anti-RPA (+) cases were affected by SARDs [118]. It is unclear whether anti-RPA antibodies 
are associated with a unique clinical and immunological subset, and further analyses in positive 
cases may help in this direction, but we can say it was positive in our patient with diffuse SSc, 
severe Raynaud’s with digital ulcers, lung and esophageal involvement, who recently developed 
thyroid cancer.  
An additional important aspect in the use of IP for screening purpose is that this technique can be 
used also to identify new autoAbs. In our cohort, we were able to identify two new patterns. First, 
we were able to see a new pattern characterized by a common set of several proteins of 140/40-
25kD in 8 SSc cases (Figure 5, panel D). This pattern is significantly associated with ACA 
positivity (p=0.008), and these patients have severe Raynaud’s with digital ulcers requiring IV 
prostacyclin (75%, 6/8 vs 7/54 ACA+, 13%; p=0.0006), with esophageal involvement in 4 cases. 
This IP pattern may correspond to the complex called hnRNP (heterogeneous nuclear 
ribonucleoprotein) which is composed of several proteins and RNAs involved in RNA processing 
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and splicing. Some of these proteins have molecular weight ranging between 32 and 45kD as the set 
of proteins we identified in our gel [119]. Several human autoAbs have been used to examine the 
components of the hnRNP complex, mainly from SLE, RA and MCTD patients, with the 
identification of predominant proteins in different diseases. For example, hnRNP-A2 (also called 
RA33) has been identified as an important autoAg in RA patients with a role in the disease 
pathogenesis [120]. This protein is the target of autoAbs called anti-RA33 that have been previously 
reported also in SLE and MCTD patients, in association with anti-Sm and -U1RNP antibodies 
[121].  
To define the 140/40-25kD pattern identified in 8 SSc cases, we performed IP-WB using two anti-
hnRNP antibodies selected by the molecular weight of the target antigen. In fact, the pattern we 
identified by protein-IP is consistent with the same pattern described for hnRNP proteins observed 
in Western Blot, but no previous study was conducted by IP using human sera from patients with 
SARDs [119]. We tested anti-hnRNP C1+C2 and anti-hnRNP L monoclonal antibodies in these 8 
samples after preparation by crosslinking of IgG to PAS beads and protein-IP protocol as described 
above, followed by WB. Results show that 6/8 SSc anti-140/40-25kD samples are positive for 
hnRNP L (Figure 5, panel E), and this may represent a new target antigen of a subset of SSc 
patients with ACA positivity and severe vasculopathy. No result was obtained from the incubation 
of hnRNP C1+C2 monoclonal antibody, and further analysis with monoclonal antibodies directed 
against other hnRNP components is still necessary.  
The second new pattern we identified is shown in Figure 6 and is characterized by a set of four 
proteins with 75-50-40-34kd molecular weight, in 6 SSc cases of our cohort. This pattern looks 
consistent with the mitochondrial antigen complex targeted by serum AMA (anti-mitochondrial 
antibodies) that represent the hallmark of primary biliary cirrohosis (PBC) in SSc patients [122, 
123], that we already previously identify in another set of PBC sera (unpublished data). PBC is a 
frequent comorbidity in SSc patients and it is commonly associated with serum ACA, and when we 
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retrospectively evaluated these 6 SSc cases with positive AMA pattern by IP we could identify 
ACA positivity at IIF and known AMA positivity by routine assays with PBC in two of them.   
 
3- POLY/DERMATOMYOSITIS (PM/DM).  
Myositis antibodies are divided into two main groups: the first group contains myositis-specific 
autoAbs that are identified almost exclusively in PM/DM patients, while the second one is for 
myositis-associated antibodies that can be present also in patients affected by other SARDs, as for 
anti-Ro/SSA antibodies that are common not only in PM/DM but also in SjS and SLE [72]. We 
tested by protein-IP and RNA-IP 22 sera collected from patients affected by PM (N=12, one of 
them affected by anti-synthetase syndrome) and DM (n=10) collected in the years 2013-2015 in our 
outpatient clinic. These patients were selected from a total of 38 PM/DM patients followed 
regularly in our outpatient clinic, based on: i)  ANA positivity at high titer but no known anti-ENA 
specificity; ii) negativity for anti-Jo-1 antibodies that is the only specificity currently tested in 
routine autoimmunity laboratories. Through protein- and RNA-IP we were able to identify rare 
autoAbs shown in Table 4 and Figure 7 (panel A and B), and in particular: anti-Mi-2 (n=2), -
TIF1γ/α (n=2), -140kD (n=1), -Ro60 (n=5), -Jo-I (n=3), -EJ (n=1), -PL-12 (n=1) and -SRP (n=1) 
antibodies. The two patients with anti-Mi-2 antibodies have typical DM with characteristic skin 
manifestations and mild myositis, and they had good response to immunosuppressive therapy as 
reported in literature [72]. In patients positive for anti-TIF1γ/α antibodies, in one case this autoAb 
was identified in a young female patient with history of cancer (Non-Hodgkin’s Lymphoma) 7 
years before the onset of DM, while the other case developed in a 65-year old man with typical 
features of DM. This autoAb is known to be associated with a paraneoplastic forms of PM/DM, and 
it has a bad prognostic value when identified in adult patients, while in juvenile forms it is not 
associated with paraneoplastic myositis, but our female DM anti- TIF1γ/α (+) patient represents an 
exception to these reports [124]. One band visible at 140kD molecular weight was identified in a 
patient affected by DM, and this is suggestive for anti-MJ or -MDA5 antibodies that need further 
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characterization by IP-WB. The presence of several autoAgs of the same molecular weight needs 
further testing to differentiate the specificities [46, 47]. Additional autoAbs identified by protein-IP 
were anti-Ro/SSA in 5 cases, and in 3 cases a double positivity with anti-Jo-1 was present. By 
protein- and RNA-IP we were able to confirm the presence of two less common anti-synthetase 
antibodies compared to the more common anti-Jo-1: we identified one positive anti-EJ (anti-glycyl 
tRNA synthetase) and one anti-PL-12 (anti-alanyl tRNA synthetase) case, in a DM and a PM with 
anti-synthetase syndrome, respectively (Figure 7, panel C). By RNA-IP we identified the 7SL 
RNA band characteristic of anti-SRP antibodies, in association with anti-Ro/SSA, in a patient with 
PM. Eight cases still have no known anti-ENA specificity and in 4 also serum ANA is undetected 
by standard IIF. However, this may be due to technical issues such as fixation steps in the 
preparation of ANA slides, causing lack of reactivity during IIF, and not to the real absence of 
autoAbs also in this set of PM/DM patients.  
 
4- PSORIATIC ARTHRITIS (PsA).  
We tested by protein-IP and RNA-IP sera from 58 patients affected by PsA collected in the years 
2013-2015 in our outpatient clinic. These patients were consecutively enrolled based on the 
negativity of serum RF and anti-CCP antibodies, and patients with different manifestation of PsA 
were included (i.e. peripheral arthritis and axial disease). Protein-IP allowed the identification of 
specific bands corresponding to anti-Ago2/Su in 2 cases, anti-Ki/SL in 2 cases and one weak anti-
PM/Scl in PsA patients (Figure 8, panels A and B). None of these patients had clinical features 
suggestive for connective tissue disease in association with PsA. As shown in Figure 8, panel B we 
were able to see immunoprecipitated proteins of variable molecular weight (48-180kD), but these 
do not correspond to known autoAbs and no common band was detected in our subsets of PsA. One 
PsA patient later developed myositis, Raynaud’s phenomenon and sclerodactyly but no specific 
autoantibody was identified by protein- and RNA-IP. Through RNA-IP we were able to identify 
one band corresponding to anti-SRP (7SL band) in one case, but no other specific autoantibody was 
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present in PsA patients (data not shown).These results indicate that PsA patients may have an 
autoimmune response similar to the one developed by RA seropositive patients, but no common 
autoAb has been identified so far to allow clinical correlations and validation as circulating 
biomarkers.  
LL37 in PsA patients.  
Besides testing our sera of PsA patients by protein- and RNA-IP to identify common autoAbs, we 
also focused our attention on the study of LL37 in our cohort, to verify the altered expression of this 
molecule also in patients affected by PsA and not only by PsO. We measured the concentration of 
LL37 in 31 PsA patients and 3 healthy controls, as shown in Figure 9 panel A. Results demonstrate 
a higher concentration of LL37 in PsA patients compared to controls, with the identification of 7 
PsA patients (7/31, 22.5%) with high concentration of LL37 (>55ng/ml) compared to the other 24 
PsA patients who do not express high concentration of LL37 (p=ns). We also compared the 
concentration of LL37 both in the serum and in the synovial fluid of three patients affected by PsA 
with active joint inflammation from which we performed knee arthrocentesis (Figure 9, panel B). 
Levels of LL37 were not different in serum and synovial fluid (p=ns), and similarly there was no 
difference in the control group represented by healthy people who underwent knee arthrocentesis 
for osteoarthritis, a disease considered degenerative and not inflammatory. These preliminary 
results may indicate that LL37 could be used as a diagnostic marker, but not as a marker of activity 
or severity of disease, as for anti-CCP antibodies in RA patients.  
 
5- BEHÇET DISEASE (BD). 
No known autoAb has been identified in sera of patients affected by BD, and for this reason, we 
analyzed by IP the sera of 45 BD patients collected by our collaborator Luca Cantarini (U.O.C. 
Reumatologia, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze; Azienda Ospedaliera 
Universitaria Senese; Ospedale Santa Maria alle Scotte; Siena, Italy) to identify possible bands 
corresponding to new autoAgs recognized by BD patients. Only in a few cases we were able to see 
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bands of unknown antigens immunoprecipitated by our sera, but no common band was detected in 
the set of samples we tested, so we cannot support the presence of specific autoAbs and perform 
clinical correlations (Figure 10, panels B and C).    
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DISCUSSION 
Systemic autoimmune rheumatic diseases (SARDs) are characterized by the presence of serum 
autoAbs directed against cellular components belonging to different tissues and organs. The role 
played by innate and adaptive immunity in the etiology and pathogenesis of SARDs is still largely 
unknown, and most reports refer to polygenic and polyenvironmental trigger factors as the primum 
movens to the onset of SARDs. As for adaptive immunity that is established by cellular key players 
such as T cells and B cells, the mechanism of autoAbs production in response to recognition of self- 
antigens is still unknown and this leads to the breakdown of immune tolerance and autoimmunity. 
In fact, the target of autoAbs is represented by self-antigens that normally play physiological roles 
in cellular activities, but in some individuals the immune response does not recognize them as self 
and this triggers the autoimmune and inflammatory response. AutoAbs can be identified also in 
healthy individuals, and for this reason they are called natural autoAbs and they are well preserved 
in vertebrates to maintain immune homeostasis [125, 126]. These natural autoAbs are primarily of 
the IgM isotype and can bind to self antigens with low affinity and low specificity, and by doing so 
they seem to have a protective role from apoptotic and tumoral antigens [127]. On the other side, 
pathogenic autoAbs are continuously identified in patients affected by SARDs, and they are 
responsible for tissue and cell damage through several proposed mechanisms: (i) induction of 
cytotoxicity after autoAb binding, through complement or phagocytic mechanisms; (ii) autoAb 
binding and modulation of cell surface receptors; (iii) immune-complex mediated damage; (iv) 
cross-reaction between intracellular and membrane antigens; (v) penetration of autoAbs into living 
cells; (vi) binding to extracellular molecules [128-132]. The mechanisms through which autoAbs 
recognize one specific multicomplex antigen among thousands expressed by a cell is not exactly 
known. Several hypothesis have been postulated, and among them the one referring to the cryptic 
epitope has been recently reevaluated to explain autoAb production in PM/DM patients [37]. The 
change in the amino acid sequence of a protein may be responsible for the change of protein 
degradation and thus lead to the formation of cryptic epitopes that are non-self to the organism thus 
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triggering the autoimmune response [13, 14]. Despite the still unknown details in the onset of 
autoimmune response and SARDs as its clinical expression, the first step to recognize the presence 
of an autoimmune response in a specific clinical setting is represented by the identification of ANA 
through the standard method IIF which is used on a regular and screening setting worldwide [16]. 
As discussed in the introduction, serum ANA are directed against cellular nuclear components and 
since 1948 with the LE cell phenomenon in SLE patients, hundreds of ANA specificities have been 
described worldwide. In the last decade, several groups and several international workshops were 
dedicated to the development of a consensus on the nomenclature and pattern description, and this 
led to the publication of official reports in 2014 and 2015 [133, 134]. Several common and rare 
patterns have been identified using HEp-2 cells as substrate, with the need to increase the correct 
report of ANA results worldwide. In fact, it has been previously demonstrated that ANA may 
represent the first alarm for the onset of a SARDs, also in the absence of clinical features of 
diseases such as SLE [8]. However, serum ANA are not disease specific and they can be produced 
also for concomitant conditions such as infection or organ-specific autoimmune disease, one of the 
most common being autoimmune thyroid disease, and then they can become negative or low-titer 
when retested [17]. This was shown also in our recent publication on the analysis of ANA and anti-
ENA in a selected population in Northern Italy, observed for a period of 15 years [18]. What makes 
the difference and increases the risk to be in front of a real case of SARDs is the high titer of ANA 
and some patterns that are more associated with clinical disease phenotypes such as ACA in SSc 
patients. These elements should bring physicians to ask for further testing as anti-dsDNA in the 
suspect of SLE if the ANA pattern is homogeneous, or to testing of anti-ENA in the suspect of other 
CTDs such as SSc and PM/DM when ANA are present in specific pattern such nucleolar. Several 
autoAbs have been identified and described since 1990s, and they are also included in the 
classification and diagnostic criteria as discussed above, but many of them are not available for the 
routine and screening commercially available tests. In diseases such as SLE and SjS no much 
progress has been done in the identification of new autoAbs as biomarkers, while in other 
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conditions such as SSc and PM/DM a lot of research has been done in the last years to identify new 
autoAbs. In order to define autoAbs as biomarkers able to trace the presence of an autoimmune 
disease and all the clinical correlations, it must be identified in a specific disease and it must be 
validated by studies based on its specificity, sensitivity, accuracy and reproducibility, so that all the 
clinicians worldwide may be able to identify specific autoAbs. One of the main problems in this 
validation of autoAbs as biomarkers is the small number of cases with a rare disease, and patients 
are spread worldwide, thus leading to bias due to enrolment, techniques of autoAb detection and 
validation of the results. As for autoAbs in PM/DM, these have been mainly discovered in the last 
decade [46-49, 135, 136] but none of them is included in the diagnostic or classification criteria 
except for anti-Jo-1 in PM patients affected by anti-synthetase syndrome [10]. Most recent autoAbs 
in SSc and PM/DM have been identified only in a research setting and are not included in routine 
autoimmunity tests with few exceptions at an international level, and this leads to additional 
problems such as (i) lack of standardization; (ii) reduced number of positive cases that could be 
studied for autoAbs clinical association; (iii) identification through time and labor consuming 
techniques such as IP; (iv) no commercially available technique such as ELISA. All these 
limitations lead to problems in the diagnosis, clinical evaluation, follow-up and therapeutic choices 
in CTD, because autoAbs can be used to characterize subsets of patients with different organ 
involvement. One of the most recent cases is represented by anti-RNAPIII antibodies in SSc with 
high risk of renal crises, that were tested in a research setting until 2006 when an ELISA kit became 
commercially available and it is now used for routine testing [64]. Similarly, we tested and 
provisionally patented a new method for detection of anti-U3/fibrillarin and -Th/To antibodies in 
SSc patients to allow faster and larger scale evaluation of these antibodies not only in a research 
setting [28]. This method uses a combination of standard RNA extraction by 
phenol/chloroform/isoamyl alcohol followed by reverse transcription and real-time PCR instead of 
running urea-PAGE gel and silver staining that can cause variable and just qualitative results. All 
these concerns address our unmet need #1, which is the lack of standard testing for most new 
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autoAbs in SSc and PM/DM patients, leading to mistakes in the patients’ management that may be 
irreversible especially when affecting internal organs. For example, a recent autoAb called anti-
MDA5 was identified in DM patients affected by rapidly progressive interstitial lung disease, so the 
lack of methods for anti-MDA5 identification could lead to worse prognosis and life-expectancy in 
anti-MDA5 positive DM patients [137-139]. On the other side, the presence of anti-Mi-2 antibodies 
in a DM patient is associated with good prognosis and quick response to immunosuppressive 
treatment for classical DM skin lesions, so the identification of anti-Mi-2 antibodies does not justify 
an aggressive treatment [140, 141].  
These considerations also lead us to our unmet need #2, which is the need to increase the number 
of cases positive for rare autoAbs in different populations, in order to have a better description of 
the meaning of autoAbs in patients affected by SARDs and belonging to different ethnic groups. In 
fact, prevalence of autoAbs in conditions such as SSc and PM/DM can vary largely according to the 
ethnic group in which it was identified, as we also demonstrated in previous studies performed in 
the Italian population [33, 46, 47, 142, 143]. For these reasons we decided to set up in our 
laboratory the two methods, protein and RNA-IP, that are considered gold-standards for the 
identification of known and unknown autoAbs, and to study the group of patients followed at our 
outpatient clinic. The main reasons to perform IP are: (i) the capacity of this technique to screen 
almost all known autoAbs performed by a single assay; (ii) the visual and qualitative confirmation 
of the reactivity of the tested human serum to the target antigen, contrary to methods such as ELISA 
in which the result may not reflect the reactivity with the actual target; (iii) antigens in IP are more 
close to the native condition compared with antigens used in other immunoassays (i.e. western blot, 
ELISA) and this is important for the identification of autoAbs that recognize multiproteins or 
multiprotein-nucleic acid complexes; (iv) protein- and RNA-IP are fundamental for the 
identification of rare autoAbs without commercial and routine assays to be tested, in association 
with the mass spectrometry analysis of the IP component. To increase the number of cases affected 
by PM/DM identified in Europe for their better evaluation from several points of view, a registry 
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called “Euromyositis” was created in 2010 and we were admitted to this group in 2015 to add data 
of our patients for a better clinical and laboratory evaluation of myositis cases in Europe 
(www.euromyositis.eu).  
Despite the advantages just mentioned, protein- and RNA-IP also have several disadvantages and 
for these reasons they are performed only in a few laboratories worldwide, mainly in a research 
setting, and they are not suitable for routine testing. In fact, they are time consuming and it takes 
weeks to have results; they are labor consuming because most buffers and material are home-made 
and not commercial; and it requires dedicated space and instruments for the use of high 
concentration of 
35
S-radioactive labeling for protein-IP (14mCi). The antigen cellular source 
commonly used is represented by K562 cells because they grow rapidly and in suspension [144], 
but alternative cell lines that can be used (i.e HeLa and HEp-2 cells) expressing the same antigens 
require more work and longer time to be radiolabeled in a large quantity.  
In our research laboratory we were able to set up protein- and RNA-IP and we first tested known 
reference sera as internal positive controls. These samples were CDC ANA reference sera provided 
through the website www.autoab.org that sends one vial of 19 samples to be used for as standard by 
laboratories worldwide. We are now part of the group called ANA standardization committee that 
aims at creating standards for ANA testing and identification following the same rules in all the 
autoimmunity laboratories worldwide, and in this group new techniques are still compared to IP as 
standard. After testing reference sera for known autoAg, we had the confirmation that IP was 
correctly performed, and in particular that the preparation of all buffers was done properly, the 
radiolabeling of K562 cells and their growth status were performed correctly as demonstrated by the 
identification of antigens such as phosphorylated topo I that is produced by well-growing K562 
cells.  
After verifying the correct performance of protein- and RNA-IP we decided to test our human 
samples of patients affected by SARDs. First, we tested human sera which had no-known anti-ENA 
despite ANA positivity, because this condition is highly suspicious for presence of an autoAb that 
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cannot be recognized by commercial techniques. As expected, SSc and PM/DM patients expressed 
several autoAbs that are considered rare and that need further characterization, as for the anti-140k 
band antibodies that may be MJ or MDA5 and for this we need further testing by IP-WB. In a 
subset of SSc patients reported as ACA despite having a complex and severe SSc we were able to 
see a new IP pattern that was recognized as the one shown in WB by hnRNPs proteins [119]. We 
tested two anti-hnRNP autoAbs based on their molecular weight, hnRNP C1+C2 and hnRNP L, but 
only hnRNP L showed reactivity when performing IP-WB as shown in our results section. This is a 
new pattern that needs to be further tested using other anti-hnRNP antibodies, and that may be 
associated with specific centromere proteins as we are planning to demonstrate by performing 
ELISA of specific CENP- proteins. If this is true, we cannot simply say that ACA positivity is 
associated with limited SSc, but in this cathegory we can also recognize other specific features of 
more aggressive vasculopathy in limited SSc, and we can conclude that not all SSc autoAbs are 
mutually exclusive. 
Another interesting set of SSc cases showed a pattern that we already observed in patients affected 
by PBC (unpublished data), represented by a set of four bands of molecular weight 75-50-40-34kD. 
When we analyzed retrospectively these six positive samples, we confirmed our association with 
the ACA pattern in all of them, and we also identified 2/6 cases with reported AMA positivity by 
routine clinical testing and a diagnosis of PBC already performed and treated. These results open to 
the possibility that an AMA pattern can be identified also by protein-IP, and this could help in the 
early diagnosis of PBC in SSc patients, a condition often underestimated until the appearance of 
clinical or laboratory features of PBC [145].  
As mentioned in unmet need #2, the identification of autoAbs by uncommon techniques such as IP 
needs to be increased in the research or routine centers performing autoimmunity tests, in order to 
increase the number of positive cases identified for specific autoAbs and to know the exact 
prevalence of autoAbs and their meaning. Recently, one autoAb identified in statin-induced 
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myositis, called anti-HMGcoA reductase antibody, was first described as a 200/100kD doublet by 
IP and recent efforts have been done to create an ELISA for its routine testing [135, 146-149].  
Among the limitations of IP, we can include the fact these techniques cannot identify several 
proteins based on their molecular weight if too low or too high, and among them citrullinated or 
carbamylated proteins present in RA patients cannot be identified by IP. This may be the first 
reason why we were not able to find results in our human sera of patients affected by PsA and also 
in those affected by a specific vasculitis such as BD. One of the main objectives of using IP in PsA 
and BD was to demonstrate the presence of reactivity and thus autoimmune activity in these 
conditions that have often been described as chronic or autoinflammatory rather than autoimmune. 
Our results show that there is no specific pattern identified by IP in these two conditions, and thus 
we were not able to identify new biomarkers probably because of technical limitations already 
mentioned or because the mechanisms underlying the disease are not autoimmune but really 
inflammatory and they do not lead to autoAb formation. In the case of PsA, in the last ten years 
much interest has been brought to the role played by the molecule LL37 as an antigen recognized 
by T cells in PsO [89, 150]. This antigen is highly expressed in PsO plaques and skin alterations 
and it is correlated with severity of PsO, while no data have been reported on LL37 and PsA. 
Starting from the hypothesis that B cells and autoAbs may not be the key players of the 
inflammatory response in PsA patients, as shown by our negative IP results, we hypothesize that 
also in PsA patients and not only in PsO LL37 may be the main antigen triggering a T-cell mediated 
response. In fact, as described in the Results, in our cohort of patients we were able to identify 7 
PsA cases expressing high concentration of LL37 even if not statistically significant compared to 
controls, somehow mirroring the partial penetrance of LL37 T cell reactivity reported by Lande and 
Colleagues [150]. These results support a possible role of this antigen also in PsA patients, and we 
aim to further study the role of LL37 by increasing the number of patients and controls, and to 
evaluate possible correlations with specific disease features (i.e. peripheral arthritis versus 
spondiloarthritis, organ involvement versus pure joint inflammation). Another aspect shown by our 
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experiments is that LL37 concentration does not change in the serum compared to synovial fluid 
obtained from the same PsA patients during active inflammation states, and this means it should not 
be considered as an activation marker but rather a disease marker. One similarity could be with anti-
CCP antibodies in RA, which are now considered markers of early diagnosis of erosive forms of 
arthritis but they are not used to follow the disease overtime. Another possible application of IP 
could be the use of an antigenic source different from K562 cells, such as a cell line derived from 
melanoma or skin cells that could express the antigenic target of PsA. The disadvantage of IP with 
this variation is that the cellular line needs to grow quickly and with high concentration to be as 
effective as K562 cells normally used for IP.  
Our results support the possibilities of setting up a technique such as IP in a research setting to 
diagnose SARDs without bias due to recent new automatic and commercial techniques, which is 
important in the view of “translational medicine” in order to “translate” research results to real-life 
clinical settings.  
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FINAL KEY MESSAGES 
 Protein and RNA-IP can be set up using specific reference samples 
 These techniques can be used for the identification of known and unknown autoAbs in 
SARDs 
 Protein--IP allowed the identification of a new pattern of different molecular weight bands 
(140/40-25kD) in a subset of SSc patients affected by limited SSc with severe vascular 
disases 
 Our IP-WB confirmed that sera with positive anti-140/40-25kD pattern react to hnRNP-L 
antibodies 
 Protein-IP allowed the identification of a pattern (75-50-40-34kD proteins) corresponding to 
AMA in SSc patients affected by PBC 
 Protein- and RNA-IP can be used together with routine laboratory tests for the early 
diagnosis and better follow-up and treatment of SARDs patients 
 LL37 could be a promising diagnostic antigen not only in PsO but also in PsA patients, as 
shown by positive samples identified in our cohort by ELISA, but it is not a marker of PsA 
activity 
 IP can be used in the setting of “translational medicine” to improve diagnosis and thus 
management of SARDs patients 
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FIGURES. 
Figure 1. Classification and diagnostic criteria of SARDs including autoAbs. Panel A. Main 
subsets of systemic autoimmune rheumatic diseases (SARDs), divided in three groups: connective 
tissue diseases, arthritis and vasculitis. Panel B. List of autoAbs currently included in the diagnostic 
criteria of SARDs, as reported by the references shown in the figure. 
Abbreviations: RA, rheumatoid arthritis, PsA psoriatic arthritis, SLE Systemic Lupus 
Erythematosus, SJS Sjögren’s syndrome, SSc Systemic Sclerosis, PM Polymyositis, DM 
Dermatomyositis, UCTD Undifferentiated connective tissue disease, MCTD Mixed connective 
tissue disease.  
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Figure 2.  Patients’ sera analyzed by protein- and RNA-IP in the present study (see section 
Patients and Methods for details).  
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Figure 3. Comparison of standard sonication with alternative methods to obtain cell lysate 
from 
35
S- radiolabeled K562. The reference sample was the anti-U1RNP+ Ro/SSA+La/SSB 
positive serum obtained from CDC ANA reference sera (www.autoab.org). We compared standard 
sonication (45 seconds twice, with one minute interval), with other two methods: (i) vortexing for 
60 seconds for 3 times, with the pellet in ice between the cycles to avoid heating; (ii) 5 cycles of 
freezing in dry ice and thawing in 37°C waterbath for 1 minute at each step. As shown in the figure, 
results are comparable and we decided to use vortexing instead of sonication for protein-IP 
radiolabeled K562 cell extract.  
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Figure 4. Reference sera. Panel A. Identification of reference sera by protein-IP (8% SDS-PAGE 
gel, fluorography and autoradiography); anti-Ro/SSA can be identified by the presence of the 
Ro60kD antigen with smiling shape, anti-La/SSB by the 48kD antigen and anti-topo I by the 110kD 
antigen with phosphorylated smear; NHS (normal human serum) is the negative control. Panel B. 
Identification of reference sera by RNA-IP (12% urea-PAGE gel, silver staining). Anti-Sm 
reference serum is recognized by the immunoprecipitation of U2-U1-U4-U5-U6 RNAs; 
U1+Ro/SSA reference serum immunoprecipitates the U1 band plus the Y-RNAs that characterize 
the Ro complex antigen; total RNA is the standard used as positive control, and negative controls 
(neg) are also run and they do not show RNA bands.  
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Figure 5.  Systemic sclerosis. Panel A. The bar graph shows the autoAb and the number of 
corresponding cases identified in SSc patients ACA (-) and topoI (-). Panel B. Anti-RPA positive 
SSc patient, recognized by the heterotrimer 70/32/14 kD shown by the arrows (Protein-IP,12% 
SDS-PAGE gel). Panel C. RNA-IP (12% urea-PAGE gel, silver staining) showing representative 
positive SSc cases for the specificities described in the figure. Panel D. Protein-IP showing a new 
pattern (indicated by squares and arrows), identified in 8 SSc patients. Panel E. IP-WB of 6 SSc 
cases positive for hnRNP L identified in the group of anti-140/40-25 kD SSc cases.  
 
- 48 - 
 
Figure 6. Systemic sclerosis. Panel A. Protein-IP results of a set of SSc patients, with positive 
autoAgs described in the figure. Panel B. Protein-IP results of a set of SSc patients, including two 
samples with bands of 75-50-40-34k that are referred as “AMA” positive and shown in the red 
square. Panel C. Protein-IP results of a set of SSc patients, including one AMA (+) in the red 
square. Panel D. Protein-IP results of a set of SSc patients, with three additional AMA (+) samples 
in the red square.  
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Figure 7. Polymyositis/dermatomyositis. Panel A. Bar graph showing the autoAb and the number 
of corresponding cases identified in PM/DM patients. Panel B. Protein-IP (12% SDS-PAGE gel) of 
representative PM/DM patients and corresponding autoAb, as shown by the arrows and by the 
associated antigen (in red) Panel C. RNA-IP (12% urea-PAGE gel, silver staining) of 
representative positive PM/DM cases, including one anti-PL-12 (+) case in a patient affected by 
anti-synthetase syndrome. Reference sera are indicated by the asterisk*.  
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Figure 8. Psoriatic arthritis. Panel A.  Protein-IP of PsA patients’ sera, where we can recognize 
autoAbs such as anti-Ago2/Su and Ki/Sl based on the molecular weight as shown. Panel B. 
Additional positive PsA cases with unknown specificity, indicated by the arrows.  
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Figure 9. LL37 in PsA. Panel A. Positive LL37 cases compared to controls (p=ns); the cut-off for 
positive LL37 samples was established at >55ng/ml (mean ± 3 standard deviations). Panel B. 
Comparison of LL37 levels in synovial fluid (SF) versus serum of three PsA patients with active 
disease (p=ns); the same comparison was also performed in SF from osteoarthritis (OA) patients 
and in serum of healthy controls (HC, p=ns).   
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Figure 10. Behcet disease (BD). Panel A. Description of the present classification of vasculitis, 
that are divided based on the size of the affected vessels (small, medium, large) and to the positivity 
or not of ANCA. BD belongs to the group of ANCA (-) vasculitis, only three vasculitis can be 
diagnosed based on the presence of ANCA with different patterns (MPO/PR3). Panel B. 
Representative results of protein-IP for BD patients (8% SDS-PAGE gel). Arrows indicate bands 
recognized as autoAg by protein-IP, but no common band was identified in our set of samples. 
Panel C. Another example of representative samples tested by protein-IP (8% SDS-PAGE gel). 
Also in this panel arrows indicate bands detected by IP but no common band was identified.  
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TABLES 
Table 1. AutoAbs in SSc and PM/DM that can be identified by protein- and RNA-IP 
according to the characteristics of the antigen described in the table.  
SSc AutoAb Target autoAg Protein-IP RNA-IP 
ACA CENP proteins -  - 
Topo1 (Scl70) Topoisomerase I 110kD with 
phosphorylation smear 
- 
RNAPs RNA polymerase 
I/II/III 
Bands at 240-220 and 
145kD (RNAPII), 197 
and 126kD (RNAPI), 
155 and 138kD 
(RNAPIII) 
- 
Th/To MRP complex - 7-2 and 8-2 RNA 
U3/fibrillarin fibrillarin 34kD U3RNA 
PM/Scl PM75 and PM 100 
protein 
100kD - 
PM AutoAb    
Jo-1 Histidyl tRNA 
synthetase 
50kD tRNA
his
 
PL-7 Threonyl tRNA 
synthetase 
80kD tRNA
thr
 
PL-12 Alanyl tRNA 
synthetase 
110kD tRNA
ala
 
EJ Glycyl tRNA 
synthetase 
75kD tRNA
gly
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SRP Signal Recognition 
Particle 
72, 68, 54, 19, 14, 9kD 7SL RNA 
DM AutoAb    
Mi-2 Helicase protein 240, 150, 72, 65, 63, 
50 and 34kD 
- 
MDA5 (CADM140) MDA5 (melanoma 
differentiation- 
associated gene 5) 
140kD - 
MJ/NXP-2 NXP2 (MORC3) 140kD - 
TIF1γ/α TIF1γ/α 155 and 140kD - 
TIF1β TIF1β 120kD - 
SAE1,2 Small ubiquitin-like 
modifier 1 (SUMO-1) 
activating enzyme 
90 and 40kD - 
Other AutoAbs    
Ro/SSA Ro60 60kD Y-RNAs 
La/SSB La 48kD Y-RNAs 
Ago2/Su Ago2 200 and 100kD - 
Ki (SL) Ki 32kD - 
U1RNP U1 ribonucleoprotein - U1RNA 
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Table 2. Main differences in the protocol for protein-IP versus RNA-IP.  
Main procedure steps Protein-IP RNA-IP 
K562 radiolabeling by 
35
S yes no 
SDS-PAGE gel yes no 
urea-PAGE gel no yes 
extraction by phenol/chloroform/isoamyl alcohol no yes 
fluorography yes no 
autoradiography yes no 
silver staining  no yes  
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Table 3. Rare autoAbs identified by protein and RNA-IP in SSc patients, excluding ACA and 
anti-topoI antibodies. Some autoAbs were identified by routine immunoblotting (IB) but not 
confirmed by IP.  
SSc rare autoAbs Routine IB 
(n.) 
Protein-IP 
(n.) 
RNA-IP  
(n.) 
IIF pattern 
Anti-RNAPIII 1 (Rp155) - - cytoplasmic 
Anti-U3/fibrillarin - - 3 speckled+nucleolar 
Anti-Th/To 1 - 2 speckled+nucleolar 
Anti-SRP - - 1 cytoplasmic 
Anti-Ago2/Su - 1 (+ topoI) - homogeneous+nucleolar 
Anti-Ro/SSA 3 3 2 homogeneous and 
nucleolar 
Anti-RPA -  1 - ACA 
Anti-NOR90 1 - - speckled+nucleolar 
Anti-PM/Scl 1 (PM100) - - nuclear dots  
Anti-Ku 1 - - speckled 
140-40/25kD 
pattern  
- 8 - ACA 
AMA - 6 - ACA 
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Table 4. Rare autoAbs identified by protein and RNA-IP in PM/DM patients.  
AutoAb Diagnosis Routine IB  
(n.) 
Protein-IP  
(n.) 
RNA-IP  
(n.) 
IIF pattern 
Anti-Jo-1 PM+ ASS 2 3 3 speckled and 
cytoplasmic 
Anti-PL-12 ASS 1 1 1 speckled+cytoplasmic 
Anti-SRP PM - -  1 (with 
Ro/SSA) 
cytoplasmic 
Anti-Mi-2 DM - 2 - homogeneous and 
speckled 
Anti-EJ DM - 1 - n/a 
Anti-TIF1γ/α DM - 2 -  speckled 
Anti-Ro60 PM/DM 5 5 5 (3 with 
anti-Jo-1) 
speckled 
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List of abbreviations. 
ACA, anti-centromere antibodies 
ACR, American College of Rheumatology 
AMA, anti-mitochondria antibodies 
ANA, anti-nuclear antibodies 
ANCA, anti-neutrophil cytoplasmic antibodies 
APCs, antigen-presenting cells 
ASS, anti-synthetase syndrome 
autoAb, autoantibody 
autoAg, autoantigen 
BD, Behçet disease 
CCP, cyclic citrullinated peptide 
CRP, C reactive protein 
CTDs, connective tissue diseases 
DM, dermatomyositis 
ELISA, enzyme-linked immunosorbent assay 
ENA, extractable nuclear antigens 
ESR, erythrocyte sedimentation rate 
hnRNP, heterogeneous nuclear ribonucleoproteins 
IB, immunoblotting 
IIF, indirect immunofluorescence 
IP, immunoprecipitation 
IP-WB, immunoprecipitation-western blot 
MDA5, melanoma differentiation associated gene 5 
NHS, normal human serum 
NXP-2, nuclear matrix protein 2 
PAS, protein A Sepharose 
PBC, primary biliary cirrhosis 
PM, polymyositis 
PsA, psoriatic arthritis 
PsO, psoriasis 
RA, rheumatoid arthritis 
RF, rheumatoid factor 
RNApol, RNA polymerase 
RNA-IP, RNA immunoprecipitation 
RPA, replication protein A 
RPILD, rapidly progressive interstitial lung disease 
SAE, small ubiquitin-like modifier activating enzyme 
SARDs, systemic autoimmune rheumatic diseases 
SLE, systemic lupus erythematosus 
SjS, Sjögren’s syndrome 
SRP, signal recognition particle 
SSc, systemic sclerosis 
TIF1, transcription intermediary factor 1 
UCTD, undifferentiated connective tissue disease 
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